Downregulating p22phox ameliorates inflammatory response in Angiotensin II-induced oxidative stress by regulating MAPK and NF- B pathways in ARPE-19 cells

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Qiu, Yiguo ^a   Tao, Lifei ^a   Lei, Chunyan ^a   Wang, Jiaming ^a   Yang, Peizeng ^a   Li, Qiuhong ^b   Lei, Bo ^a  

^a THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; CCL2 PROTEIN, HUMAN; CYBA PROTEIN, HUMAN; CYBB PROTEIN, HUMAN; IL6 PROTEIN, HUMAN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; MAPK1 PROTEIN, HUMAN; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCYTE CHEMOTACTIC PROTEIN 1; NOX1 PROTEIN, HUMAN; NOX4 PROTEIN, HUMAN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SMALL INTERFERING RNA;

ANTAGONISTS AND INHIBITORS; CELL LINE; CYTOLOGY; DRUG EFFECTS; EPITHELIUM CELL; GENE EXPRESSION REGULATION; GENETICS; HUMAN; INFLAMMATION; METABOLISM; OXIDATIVE STRESS; PRIMARY CELL CULTURE; RETINAL PIGMENT EPITHELIUM; SIGNAL TRANSDUCTION;

ANGIOTENSIN II; CELL LINE; CHEMOKINE CCL2; EPITHELIAL CELLS; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; INTERLEUKIN-6; INTERLEUKIN-8; MEMBRANE GLYCOPROTEINS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NADPH OXIDASE; NF-KAPPA B; OXIDATIVE STRESS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PRIMARY CELL CULTURE; RETINAL PIGMENT EPITHELIUM; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 84942781986     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep14362     Document Type: Article

References (58)

1. Aslan, M., Cort, A. & Yucel, I. Oxidative and nitrative stress markers in glaucoma. Free Radic Biol Med 45, 367-376 (2008).
2. Loane, E., Kelliher, C., Beatty, S. & Nolan, J. M. The rationale and evidence base for a protective role of macular pigment in agerelated maculopathy. Br J Ophthalmol 92, 1163-1168 (2008).
3. Kowluru, R. A. Diabetic retinopathy: mitochondrial dysfunction and retinal capillary cell death. Antioxid Redox Signal 7, 1581-1587 (2005).
4. Zhou, J., Jang, Y. P., Kim, S. R. & Sparrow, J. R. Complement activation by photooxidation products of A2E, a lipofuscin constituent of the retinal pigment epithelium. Proc Natl Acad Sci USA 103, 16182-16187 (2006).
5. Hollyfield, J. G. et al. Oxidative damage-induced inflammation initiates age-related macular degeneration. Nat Med 14, 194-198 (2008).
6. Antonicelli, F. et al. Nacystelyn inhibits oxidant-mediated interleukin-8 expression and NF-kappaB nuclear binding in alveolar epithelial cells. Free Radic Biol Med 32, 492-502 (2002).
7. Boots, A. W., Haenen, G. R. & Bast, A. Health effects of quercetin: from antioxidant to nutraceutical. Eur J Pharmacol 585, 325-337 (2008).
8. Cao, X., Liu, M., Tuo, J., Shen, D. & Chan, C. C. The effects of quercetin in cultured human RPE cells under oxidative stress and in Ccl2/Cx3cr1 double deficient mice. Exp Eye Res 91, 15-25 (2010).
9. Babior, B. M. NADPH oxidase. Curr Opin Immunol 16, 42-47 (2004).
10. Bedard, K. & Krause, K. H. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 87, 245-313 (2007).
11. Zafari, A. M. et al. Role of NADH/NADPH oxidase-derived H2O2 in angiotensin II-induced vascular hypertrophy. Hypertension 32, 488-495 (1998).
12. Rao, P. V., Maddala, R., John, F. & Zigler, J. S., Jr. Expression of nonphagocytic NADPH oxidase system in the ocular lens. Mol Vis 10, 112-121 (2004).
13. McCrann, D. J., Yang, D., Chen, H., Carroll, S. & Ravid, K. Upregulation of Nox4 in the aging vasculature and its association with smooth muscle cell polyploidy. Cell Cycle 8, 902-908 (2009).
14. Tong, X., Hou, X., Jourd'heuil, D., Weisbrod, R. M. & Cohen, R. A. Upregulation of Nox4 by TGF{beta}1 oxidizes SERCA and inhibits NO in arterial smooth muscle of the prediabetic Zucker rat. Circ Res 107, 975-983 (2010).
15. Gao, H. M., Zhou, H. & Hong, J. S. NADPH oxidases: novel therapeutic targets for neurodegenerative diseases. Trends Pharmacol Sci 33, 295-303 (2012).
16. De Leo, F. R., Ulman, K. V., Davis, A. R., Jutila, K. L. & Quinn, M. T. Assembly of the human neutrophil NADPH oxidase involves binding of p67phox and flavocytochrome b to a common functional domain in p47phox. J Biol Chem 271, 17013-17020 (1996).
17. Wilkinson-Berka, J. L. et al. NADPH oxidase, NOX1, mediates vascular injury in ischemic retinopathy. Antioxid Redox Signal 20, 2726-2740 (2014).
18. Al-Shabrawey, M. et al. Role of NADPH oxidase in retinal vascular inflammation. Invest Ophthalmol Vis Sci 49, 3239-3244 (2008).
19. Lambeth, J. D., Cheng, G., Arnold, R. S. & Edens, W. A. Novel homologs of gp91phox. Trends Biochem Sci 25, 459-461 (2000).
20. Li, Q. et al. Downregulation of p22phox in retinal pigment epithelial cells inhibits choroidal neovascularization in mice. Mol Ther 16, 1688-1694 (2008).
21. Wang, Y. & Lou, M. F. The regulation of NADPH oxidase and its association with cell proliferation in human lens epithelial cells. Invest Ophthalmol Vis Sci 50, 2291-2300 (2009).
22. Suzuki, Y. et al. Inflammation and angiotensin II. Int J Biochem Cell Biol 35, 881-900 (2003).
23. Benigni, A., Cassis, P. & Remuzzi, G. Angiotensin II revisited: new roles in inflammation, immunology and aging. EMBO Mol Med 2, 247-257 (2010).
24. Pearson, G. et al. Mitogen-Activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 22, 153-183 (2001).
25. Savoia, C. & Schiffrin, E. L. Inflammation in hypertension. Curr Opin Nephrol Hypertens 15, 152-158 (2006).
26. Fukumoto, M. et al. Involvement of angiotensin II-dependent vascular endothelial growth factor gene expression via NADPH oxidase in the retina in a type 2 diabetic rat model. Curr Eye Res 33, 885-891 (2008).
27. Cai, J., Nelson, K. C., Wu, M., Sternberg, P., Jr. & Jones, D. P. Oxidative damage and protection of the RPE. Prog Retin Eye Res 19, 205-221 (2000).
28. Holtkamp, G. M., Kijlstra, A., Peek, R. & de Vos, A. F. Retinal pigment epithelium-immune system interactions: cytokine production and cytokine-induced changes. Prog Retin Eye Res 20, 29-48 (2001).
29. Philp, N. J., Wang, D., Yoon, H. & Hjelmeland, L. M. Polarized expression of monocarboxylate transporters in human retinal pigment epithelium and ARPE-19 cells. Invest Ophthalmol Vis Sci 44, 1716-1721 (2003).
30. Dunn, K. C., Aotaki-Keen, A. E., Putkey, F. R. & Hjelmeland, L. M. ARPE-19, a human retinal pigment epithelial cell line with differentiated properties. Exp Eye Res 62, 155-169 (1996).
31. Petry, A., Weitnauer, M. & Gorlach, A. Receptor activation of NADPH oxidases. Antioxid Redox Signal 13, 467-487 (2010).
32. Wilkinson-Berka, J. L., Rana, I., Armani, R. & Agrotis, A. Reactive oxygen species, Nox and angiotensin II in angiogenesis: implications for retinopathy. Clin Sci (Lond) 124, 597-615 (2013).
33. Ruiz-Ortega, M. et al. Role of the renin-Angiotensin system in vascular diseases: expanding the field. Hypertension 38, 1382-1387 (2001).
34. Ruiz-Ortega, M. et al. Angiotensin II activates nuclear transcription factor kappaB through AT(1) and AT(2) in vascular smooth muscle cells: molecular mechanisms. Circ Res 86, 1266-1272 (2000).
35. Chen, X. L., Tummala, P. E., Olbrych, M. T., Alexander, R. W. & Medford, R. M. Angiotensin II induces monocyte chemoattractant protein-1 gene expression in rat vascular smooth muscle cells. Circ Res 83, 952-959 (1998).
36. Kranzhofer, R. et al. Angiotensin induces inflammatory activation of human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 19, 1623-1629 (1999).
37. Strauss, O. The retinal pigment epithelium in visual function. Physiol Rev 85, 845-881 (2005).
38. Miceli, M. V., Liles, M. R. & Newsome, D. A. Evaluation of oxidative processes in human pigment epithelial cells associated with retinal outer segment phagocytosis. Exp Cell Res 214, 242-249 (1994).
39. Ambasta, R. K. et al. Direct interaction of the novel Nox proteins with p22phox is required for the formation of a functionally active NADPH oxidase. J Biol Chem 279, 45935-45941 (2004).
40. DeLeo, F. R. et al. Processing and maturation of flavocytochrome b558 include incorporation of heme as a prerequisite for heterodimer assembly. J Biol Chem 275, 13986-13993 (2000).
41. OBrien, W. J., Krema, C., Heimann, T. & Zhao, H. Expression of NADPH oxidase in rabbit corneal epithelial and stromal cells in culture. Invest Ophthalmol Vis Sci 47, 853-863 (2006).
42. ten Freyhaus, H. et al. Novel Nox inhibitor VAS2870 attenuates PDGF-dependent smooth muscle cell chemotaxis, but not proliferation. Cardiovasc Res 71, 331-341 (2006).
43. Sedeek, M. et al. Critical role of Nox4-based NADPH oxidase in glucose-induced oxidative stress in the kidney: implications in type 2 diabetic nephropathy. Am J Physiol Renal Physiol 299, F1348-1358 (2010).
44. Yun, M. R. et al. NAD(P)H oxidase-stimulating activity of serum from type 2 diabetic patients with retinopathy mediates enhanced endothelial expression of E-selectin. Life Sci 78, 2608-2614 (2006).
45. Al-Shabrawey, M. et al. Role of NADPH oxidase and Stat3 in statin-mediated protection against diabetic retinopathy. Invest Ophthalmol Vis Sci 49, 3231-3238 (2008).
46. Dvoriantchikova, G., Grant, J., Santos, A. R., Hernandez, E. & Ivanov, D. Neuronal NAD(P)H oxidases contribute to ROS production and mediate RGC death after ischemia. Invest Ophthalmol Vis Sci 53, 2823-2830 (2012).
47. Al-Shabrawey, M. et al. Inhibition of NAD(P)H oxidase activity blocks vascular endothelial growth factor overexpression and neovascularization during ischemic retinopathy. Am J Pathol 167, 599-607 (2005).
48. Wang, H., Yang, Z., Jiang, Y. & Hartnett, M. E. Endothelial NADPH oxidase 4 mediates vascular endothelial growth factor receptor 2-induced intravitreal neovascularization in a rat model of retinopathy of prematurity. Mol Vis 20, 231-241 (2014).
49. Chen, P., Guo, A. M., Edwards, P. A., Trick, G. & Scicli, A. G. Role of NADPH oxidase and ANG II in diabetes-induced retinal leukostasis. Am J Physiol Regul Integr Comp Physiol 293, R1619-1629 (2007).
50. Modlinger, P. et al. RNA silencing in vivo reveals role of p22phox in rat angiotensin slow pressor response. Hypertension 47, 238-244 (2006).
51. Roux, P. P. & Blenis, J. ERK and p38 MAPK-Activated protein kinases: A family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev 68, 320-344 (2004).
52. Kudoh, S. et al. Angiotensin II stimulates c-Jun NH2-Terminal kinase in cultured cardiac myocytes of neonatal rats. Circ Res 80, 139-146 (1997).
53. Pellieux, C., Sauthier, T., Aubert, J. F., Brunner, H. R. & Pedrazzini, T. Angiotensin II-induced cardiac hypertrophy is associated with different mitogen-Activated protein kinase activation in normotensive and hypertensive mice. J Hypertens 18, 1307-1317 (2000).
54. Pons, M., Cousins, S. W., Alcazar, O., Striker, G. E. & Marin-Castano, M. E. Angiotensin II-induced MMP-2 activity and MMP-14 and basigin protein expression are mediated via the angiotensin II receptor type 1-mitogen-Activated protein kinase 1 pathway in retinal pigment epithelium: implications for age-related macular degeneration. Am J Pathol 178, 2665-2681 (2011).
55. Mollnau, H. et al. Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ Res 90, E58-65 (2002).
56. Costanzo, A. et al. Endothelial activation by angiotensin II through NFkappaB and p38 pathways: Involvement of NFkappaBinducible kinase (NIK), free oxygen radicals, and selective inhibition by aspirin. J Cell Physiol 195, 402-410 (2003).
57. Wang, T., Zhang, X. & Li, J. J. The role of NF-kappaB in the regulation of cell stress responses. Int Immunopharmacol 2, 1509-1520 (2002).
58. Qiu, Y. et al. Angiotensin-converting enzyme 2 (ACE2) activator diminazene aceturate ameliorates endotoxin-induced uveitis in mice. Invest Ophthalmol Vis Sci 55, 3809-3818 (2014).